Kodiak Sciences (KOD) Assets Average (2018 - 2026)
Kodiak Sciences' (KOD) quarterly Assets Average came in at $328.8 million in Q1 2026, up 3.8% YoY from $316.7 million in Q1 2025, and up 15.44% on a QoQ basis from $284.8 million in Q4 2025.
Analysis
Kodiak Sciences (KOD) Assets Average (2018 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 9 years of Assets Average data on file, last reported at $328.8 million in Q1 2026.
- Quarterly Assets Average rose 3.8% year-over-year to $328.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $328.8 million (up 3.8% YoY) and the FY2025 annual result came in at $343.6 million, down 15.69% from the prior year.
- Assets Average improved to $328.8 million in Q1 2026, from $284.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $877.3 million in Q1 2022 to a low of $237.4 million in Q3 2025.
- A 5-year average of $503.2 million and a median of $457.1 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average sank 38.68% — and 2026, when it rose 3.8%.
- Tracing KOD's Assets Average over 5 years: stood at $695.3 million in 2022, then slipped by 26.15% to $513.5 million in 2023, then slumped by 31.04% to $354.1 million in 2024, then decreased by 19.58% to $284.8 million in 2025, then climbed by 15.44% to $328.8 million in 2026.
- The last three Assets Average figures came in at $328.8 million (Q1 2026), $284.8 million (Q4 2025), and $237.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | 281.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 281.41 Mn |
| Mar 31, 2026 | 328.77 Mn |
| Dec 31, 2025 | 284.80 Mn |
| Sep 30, 2025 | 237.40 Mn |
| Jun 30, 2025 | 277.32 Mn |
| Mar 31, 2025 | 316.74 Mn |
| Dec 31, 2024 | 354.12 Mn |
| Sep 30, 2024 | 387.12 Mn |
| Jun 30, 2024 | 418.17 Mn |
| Mar 31, 2024 | 457.07 Mn |
| Dec 31, 2023 | 513.51 Mn |
| Sep 30, 2023 | 568.66 Mn |
| Jun 30, 2023 | 615.00 Mn |
| Mar 31, 2023 | 653.48 Mn |
| Dec 31, 2022 | 695.31 Mn |
| Sep 30, 2022 | 752.95 Mn |
| Jun 30, 2022 | 816.10 Mn |
| Mar 31, 2022 | 877.25 Mn |
| Dec 31, 2021 | 931.21 Mn |
| Sep 30, 2021 | 977.90 Mn |